Innate Pharma to Showcase Pipeline Progress at Leerink Partners Global Healthcare Conference

Innate Pharma (NASDAQ: IPHA), a clinical-stage biotechnology company specializing in immunotherapies for cancer patients, has announced its participation in the upcoming Leerink Partners 2025 Global Healthcare Conference. The event, scheduled for March 10-12, 2025, in Miami, Florida, will provide an opportunity for the company to present its pipeline progress and engage with investors, analysts, and industry professionals.



Innate Pharma's executive team will participate in a fireside chat on Tuesday, March 11, 2025, from 3:00 to 3:30 pm ET, where they will discuss the company's recent achievements, clinical trial updates, and strategic vision. Additionally, the team will host one-on-one meetings with attendees throughout the conference, allowing for more in-depth discussions and networking opportunities.



The company's participation in the conference aligns with its overall strategy and growth prospects, as it seeks to raise awareness about its innovative pipeline and engage with potential partners and investors. Innate Pharma's pipeline includes several promising product candidates, such as lacutamab, an anti-KIR3DL2 antibody in Phase 2 clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as refractory Sézary syndrome. Additionally, monalizumab, an immune checkpoint inhibitor, is in Phase 3 clinical trials to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer.



Innate Pharma's presentation at the conference is expected to provide valuable insights into the company's progress and potential, which could impact investor sentiment and stock price. The company's strong pipeline and clinical trial progress, as well as its strategic vision and partnerships, are likely to be key topics of discussion during the fireside chat and one-on-one meetings.

In conclusion, Innate Pharma's participation in the Leerink Partners 2025 Global Healthcare Conference is a strategic move that showcases the company's commitment to advancing immunotherapies and driving growth in the global healthcare market. Investors and industry professionals should pay close attention to the company's presentation and discussions at the conference, as they may provide valuable insights into the company's progress and potential.